Navigation Links
Preclinical study finds drug helps against pancreatic cancer
Date:10/24/2013

October 23, 2013(BRONX, NY)An investigational drug that disrupts tumor blood vessels shows promise against a rare type of pancreatic cancer, scientists at Albert Einstein College of Medicine of Yeshiva University have found. Their results were presented October 20 during a poster session at an international cancer conference.

The drug Zybrestat selectively targets and collapses tumor blood vessels, depriving the tumor of oxygen and making its cells die. In experiments involving a mouse model of pancreatic neuroendocrine tumors, Einstein scientists found that infusing mice with Zybrestat three times per week for four weeks resulted in significant antitumor activity compared with control mice given a placebo.

The findings were presented in Boston at the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics. Presenting for Einstein was ZiQiang Yuan, M.D., research assistant professor of surgery at Einstein. The senior author is Steven K. Libutti, M.D., professor of genetics at Einstein and professor and vice chair of surgery at Einstein and Montefiore Medical Center, the University Hospital and academic medical center for Einstein.

Pancreatic cancer is the fourth-leading cause of cancer death in the U.S. According to the National Cancer Institute, more than 45,000 Americans will be diagnosed with pancreatic cancer in 2013 and more than 38,000 will die of the disease. Exocrine pancreatic cancer, the more common and usually fatal type, begins in the ducts that carry pancreatic juices. The Einstein study involved endocrine pancreatic cancerthe much less common and more curable form of the disease that originates in pancreatic cells that make hormones (and that caused the death of Apple co-founder Steve Jobs).

All the mice in the study had insulinomasendocrine tumors that form in pancreatic cells that make insulin, the hormone that controls glucose levels in the blood. This type of tumor can make the pancreas over-secrete insulin. The Einstein researchers found that treating the mice with Zybrestat caused a significant and sustained decrease in circulating insulin and also significantly reduced tumor size.

Zybrestat has been evaluated in clinical trials involving patients with anaplastic thyroid cancer, a highly aggressive cancer for which there are no approved treatments. The drug is made by OXiGENE, Inc., a biotech company based in San Francisco, CA.

Dr. Libutti is also director of the Montefiore Einstein Center for Cancer Care and associate director, clinical services at the Albert Einstein Cancer Center. This research was supported in part by OXiGENE, Inc. through a sponsored research agreement with Einstein. The authors report no conflicts of interest.


'/>"/>

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
2. Genetically-engineered preclinical models predict pharmacodynamic response
3. Preclinical study identifies master proto-oncogene that regulates ovarian cancer metastasis
4. Preclinical tests shows agent stops slippery proteins from binding, causing Ewing sarcoma
5. Mayo Clinic: Preclinical tests may lead to new approach to treat CNS lymphoma
6. Study Suggests Vaccine May Help Kids With Brain Cancer
7. Study reveals how cancer drug causes diabetic-like state
8. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
9. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
10. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
11. No Added Cancer Risk From Hip Replacement Materials: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Smithtown, New York (PRWEB) , ... January 16, ... ... group, SightMD today announced the addition of Victor Giamos, MD to ... Officer of SightMD and Managing Partner at North Shore Eye Care, a division ...
(Date:1/16/2017)... ... ... are well-aware of the following facts at present:, Flu and ... no effect on keeping this particularly bad strain of the flu away , ... sniffling , These facts are well-known among the team at Woodard! About ...
(Date:1/16/2017)... CITY, UT (PRWEB) , ... January 16, 2017 , ... ... disease not only to treat, but to test for, as well. The money spent ... billion every year.(1) Doctors in the U.S. screen patients for cancer more than in ...
(Date:1/15/2017)... ... , ... In this role, Courtney will be responsible for developing new business ... friendly mark. This certification program was created by ASL and the nonprofit Asthma and ... suitable for the 60+ million people living in the U.S. with asthma and allergies. ...
(Date:1/15/2017)... ... 15, 2017 , ... "On Tour is a music themed slideshow production package ... Christina Austin - CEO of Pixel Film Studios. , On Tour’s new slide ... and animation of their slideshows. Place each slide on top of another slide or ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... , January 13, 2017 This ... see how they have fared at yesterday,s closing bell: ... Biopharma Inc. (NASDAQ: GALE ), and ACADIA ... harness cellular and biomolecular processes to develop technologies and ... environmental footprint, feed the hungry, use less and cleaner ...
(Date:1/13/2017)... 2017 The 2016 election resulted in ... states voting in favor of legalizing cannabis for recreational use, ... in the U.S. In addition, the state of ... cannabis products sales. The ArcView Group has published an updated ... cannabis sales in the U.S. last year reached $6.7 billion, a ...
(Date:1/13/2017)... 2017   JDRF , the leading global ... pleased to announce that after more than a ... & Medicaid Services (CMS) has recognized continuous glucose ... use in making diabetes treatment decisions as durable ... eligible for coverage under Medicare. JDRF has been ...
Breaking Medicine Technology: